De Boulle Koenraad L V
Aalst Dermatology Group, 43 Leopoldlaan 9300 Aalst, Belgium.
Expert Opin Pharmacother. 2007 Jun;8(8):1059-72. doi: 10.1517/14656566.8.8.1059.
Injection of botulinum neurotoxin type A has rapidly become the most common non-surgical cosmetic procedure performed, due to its exceptional safety profile, as well as its ability to rejuvenate and enhance a number of facial areas. There are several marketed botulinum neurotoxin preparations, but products are not interchangeable as each possesses distinctive characteristics that are attributed to the unique toxin purification and manufacturing processes. These differences can emerge in the form of potency, duration of effect and the potential for migration outside targeted tissue, causing unwanted effects. However, although there are established preclinical pharmacologic and therapeutic differences between products, there are few well-controlled clinical comparisons in facial aesthetics. It is important for clinicians using these products to understand these differences as they relate to achieving desired outcomes for patients who seek improved facial aesthetics.
由于A型肉毒杆菌神经毒素具有卓越的安全性,以及能够使多个面部区域恢复活力和改善外观,其注射已迅速成为最常见的非手术美容程序。市场上有几种肉毒杆菌神经毒素制剂,但产品不可互换,因为每种产品都具有独特的特性,这些特性归因于独特的毒素纯化和生产工艺。这些差异可能以效力、效果持续时间以及在目标组织外迁移的可能性等形式出现,从而导致不良影响。然而,尽管产品之间存在既定的临床前药理学和治疗差异,但在面部美学方面,很少有严格对照的临床比较。对于使用这些产品的临床医生来说,了解这些与为寻求改善面部美学的患者实现预期效果相关的差异非常重要。